ASCO GI 2023 | Immunotherapy & local ablative therapy in mCRC with liver metastases

Jenny Seligmann, MBChB, PhD, University of Leeds, Leeds, UK, discusses findings from the Phase II EORTC ILOC study (2017-001375-22) of durvalumab and tremelimumab followed by radiofrequency ablation (RFA) or stereotactic radiotherapy (SBRT) in patients with metastatic colorectal cancer (mCRC) with unresectable liver metastases. Whilst previous studies have suggested the synergistic potential of local ablative treatments and immunotherapy in targeting liver metastases, outcomes were not improved in the trial. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Gastrointestinal Cancers (GI) Symposium in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

View our new feature exploring genomic biomarkers in metastatic colorectal cancer here: https://bit.ly/3DcSevZ